Following the recommendations of the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and state public health officials, Kaiser Permanente has resumed use of the Johnson & Johnson/Janssen COVID-19 vaccine, as supply allows.
Our infectious disease physicians and other experts reviewed all available data related to the rare instances of blood clotting that caused the CDC and FDA to temporarily pause use of the vaccine. This data shows that the J&J vaccine’s known and potential benefits outweigh its known and potential risks.
We have and will continue to follow federal and state instructions that women under 50 are told about the rare but increased risk of blood clots. We’ll also follow all other clinical guidance from the FDA and CDC to ensure the safe and effective use of the J&J vaccine.
For more information on the vaccine, visit kp.org/covidvaccine. You can also call our 24/7 KP COVID Vaccine InfoLine at 1‑877-808-9233 (available in English and Spanish) for regular recorded updates.
